Pathos AI, Bristol Myers Squibb, and Tempus AI have partnered to create AI tools for drug development in Alzheimer's disease and other neurological disorders. The collaboration involves a dataset from hundreds of thousands of patients, which will be used to track outcomes and speed research into disease biology. Pathos will license this data under a five-year, $55 million agreement and apply its AI platform, Pathos Foundry, to study the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials. Bristol Myers will gain non-exclusive strategic access to Pathos Foundry across its broader portfolio, as well as three-year…
Key points
Pathos AI, Bristol Myers Squibb, and Tempus AI have formed a partnership to create AI too…: Pathos AI, Bristol Myers Squibb, and Tempus AI have formed a partnership to create AI tools for drug development in Alzheimer's disease and other neurological disorders.
The collaboration involves a dataset from hundreds of thousands of patients, which will b…: The collaboration involves a dataset from hundreds of thousands of patients, which will be used to track outcomes and speed research into disease biology.
Pathos will license this data under a five-year, $55 million agreement and apply its AI p…: Pathos will license this data under a five-year, $55 million agreement and apply its AI platform, Pathos Foundry, to study the dataset at scale, generate and test hypotheses
Sources checked by our analysis pipeline: 1
Oct 23 : Pathos AI said on Friday it had entered into a collaboration with Bristol Myers Squibb and Tempus AI to develop artificial intelligence tools for drug development in Alzheimer's disease and other neurological disorders.
Pathos AI also raised $237 million in a Series E funding round led by Bristol Myers that valued the New York-based company at about $3 billion, with participation from existing investors.
Here are some other details:
• Tempus will build a dataset from hundreds of thousands of patients with neurological disorders to help track outcomes and speed research into disease biology
• Pathos will license the data from Tempus under a five-year, $55 million agreement
• Pathos will apply its AI platform, Pathos Foundry, to study the dataset at scale, generate and test hypotheses on disease biology, and inform the design of more targeted, adaptive clinical trials
• Bristol Myers will gain non-exclusive strategic access to Pathos Foundry across its broader portfolio, as well as three-year exclusive rights to use the platform for its neuroscience development programs
• Proceeds from the financing will be used to further scale the Foundry platform's capabilities and accelerate development of its AI-driven pipeline, including advancing experimental cancer drug, JSKN016
• The funding will help advance development of other cancer programs including an AstraZeneca-partnered experimental breast cancer drug
A study on macaques' behavior and health reveals that exposure to a grape sitting on a pile of poop might help prevent a disease outbreak. Scientists found that macaques who hadn't experienced the outbreak were more likely to eat the grape, suggesting heightened sensitivity to disgust could protect against infection.
Finland is set to open the world's first permanent underground nuclear waste repository, marking a significant milestone in the country's nuclear waste management. The government has granted an operating license for the Onkalo facility, located in western Finland, which will provide a secure and permanent solution for Finland's spent nuclear fuel. The repository, capable of storing up to 6,500 tonnes of uranium, will be sealed with bentonite clay and a steel-reinforced concrete plug, and will remain highly radioac…
Briefing:** Friday the 13th prequel series based on Jason's mother, "Crystal Lake," initially garnered some interest but quickly became disappointing. The focus on the character's mother, Pam Voorhees, seems to have overshadowed the core elements of the franchise, leading to a lack of excitement and a decline in viewer satisfaction. The series has been criticized for not living up to the expectations set by the original Friday the 13th films, which have a strong following and a well-established fan base.